Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;615(7953):687–696. doi: 10.1038/s41586-022-05531-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 3 — a) Phenotype of CD4+ T cells (left) and CD8+ T cells (right) in incoming leukapheresis and final cell product from dosed patients. Bars represent individual NeoTCR-T cell products for each patient (up-to-3 neoTCRs per patient). For Dex+ CD4+ T cells, only products where the peptide-HLA multimer binds the inserted TCR in the absence of the CD8 co-receptor have data. T cell subset abbreviations are as follows: EFF (effector), EM (effector memory), TM (transitional memory), CM (central memory), MSC (memory stem cell), N (naïve). b) T cell activation and phenotypic markers in the manufactured FCP. Percentage of CD4+ (top) or CD8+ (bottom) NeoTCR+ (left) or NeoTCR- (right) cells in the manufactured product that express the indicated surface markers. For NeoTCR+ CD4+ T cells, only products where the dextramer binds the inserted TCR in the absence of the CD8 co-receptor have data. c) NeoTCR knock-in efficiency of the endogenous TCR improved with changes in the manufacturing process. NeoTCR+ percentages were significantly different with the different process versions (***p = 0.0006 by ANOVA; v2.1 and v3.0 were significantly better than process v2.0: *p = 0.0218 and **p = 0.0029, respectively, by Tukey’s multiple comparisons test, v2.0: n = 30, v2.1: n = 9, v3.0, n = 3). d) Cell counts of neoTCR+ cells (left) and total cells (right) in manufacturing process v2.0 (n = 30) compared to process v2.1 (n = 9) and v3.0 (n = 3). Differences not significant (ns) by one-way ANOVA.